{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:48Z","timestamp":1761562488617,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Despite high efficacy of current direct\u2010acting antiviral agents (DAAs) in treating chronic hepatitis C virus (HCV) infection, a small portion of patients fail treatment. QUARTZ\u2010I was a phase 2, open\u2010label, multicenter, two\u2010part study that assessed the safety and efficacy of ombitasvir\/paritaprevir\/ritonavir (OBV\/PTV\/r) with dasabuvir (DSV) with or without the addition of sofosbuvir (SOF) and\/or ribavirin (RBV) in DAA treatment\u2010experienced adults with chronic HCV GT1 infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Genotype 1 HCV\u2010infected patients with or without compensated cirrhosis had prior treatment failure to any DAA (part 1) or ledipasvir\/SOF (part 2). Patients received OBV\/PTV\/r\u00a0+\u00a0DSV\u00a0\u00b1\u00a0SOF with or without RBV for 12 or 24 weeks. The primary endpoint of this study is the percentage of patients achieving sustained virologic response at post\u2010treatment week 12 (SVR12).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In part 1 of the study, 95.5% (21\/22) of patients achieved SVR12, and in part 2, the SVR12 rate was 85.7% (6\/7). Most adverse events (AEs) were mild and moderate in severity. Two serious AEs occurred and were assessed as not being related to study drug, of which one resulted in study drug discontinuation. Two patients experienced grade 3 elevations of serum alanine aminotransferase, and no other grade \u22653 laboratory abnormalities were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The multi\u2010targeted regimen of OBV\/PTV\/r\u00a0+\u00a0DSV\u00a0\u00b1\u00a0SOF with or without RBV was effective in the treatment of patients who failed previous DAA regimens including NS3\/4A protease and NS5A and NS5B polymerase inhibitors. These results provide a promising outcome for patients that traditionally had limited treatment options.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.25448","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T18:49:58Z","timestamp":1551898198000},"page":"1307-1312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct\u2010acting antiviral therapy"],"prefix":"10.1002","volume":"91","author":[{"given":"Fred","family":"Poordad","sequence":"first","affiliation":[{"name":"The Texas Liver Institute\/University of Texas Health San Antonio Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bennett","sequence":"additional","affiliation":[{"name":"Medical Associates Research Group San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Sepe","sequence":"additional","affiliation":[{"name":"Liver Center, University Gastroenterology Providence Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Cohen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Reindollar","sequence":"additional","affiliation":[{"name":"Piedmont Healthcare\/Carolinas Center for Liver Disease Statesville North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Everson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology University of Colorado Denver School of Medicine Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond W.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Gastroenterology Group of Naples PA Naples Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Siddique","sequence":"additional","affiliation":[{"name":"Digestive Disease Institute Virginia Mason Hospital and Medical Center Seattle Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Greg","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Parkway Medical Center Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Pilot\u2010Matias","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal","family":"Abunimeh","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Cohen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-3698","authenticated-orcid":false,"given":"Ziad","family":"Younes","sequence":"additional","affiliation":[{"name":"GastroOne Germantown Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,19]]},"reference":[{"key":"e_1_2_7_1_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.6"},{"key":"e_1_2_7_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.015"},{"key":"e_1_2_7_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.005"},{"key":"e_1_2_7_1_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.003"},{"key":"e_1_2_7_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30071-4"},{"key":"e_1_2_7_1_7_1","unstructured":"MAVIRET\u00a0(glecaprevir\/pibrentasvir) [package insert] package insert. AbbVie Inc. North Chicago IL USA."},{"key":"e_1_2_7_1_8_1","unstructured":"VOSEVI (sofosbuvir\/velpatasvir\/voxilaprevir) [package insert]. Gilead Sciences. Foster City CA USA."},{"key":"e_1_2_7_1_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.007"},{"key":"e_1_2_7_1_10_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3053"},{"key":"e_1_2_7_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv564"},{"key":"e_1_2_7_1_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01913-15"},{"key":"e_1_2_7_1_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix916"},{"key":"e_1_2_7_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_2_7_1_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29256"},{"key":"e_1_2_7_1_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29130"},{"key":"e_1_2_7_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_7_1_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"e_1_2_7_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_7_1_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1396-0"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25448","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.25448","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T22:28:53Z","timestamp":1694384933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,19]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1002\/jmv.25448"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25448","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2019,3,19]]},"assertion":[{"value":"2018-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}